department

Clinical
Regulatory
Medical Affairs
Commercial
R&D / Discovery
Biostatistics / Data
Manufacturing / CMC
Market Access

therapeutic area

Oncology
Immunology
Neuroscience
Cardiovascular
Metabolic
Rare Disease
Infectious Disease

location & type

Remote Only
US Only
California
Massachusetts
Internships
Phase 3 Roles
All Jobs →

when

Latest
Archive

by source

All Sources
Sources Page

by activity

Most Active
Biggest Pipelines
Recently Active

hiring

Companies Hiring Now
Big Pharma Roles
All Companies →

Drugs & Pipeline

intelligence

Drugs
Patent Cliff

research

Publications
Topics

window

Next 90 Days
All (incl. Past)

by type

PDUFAs
Approvals
Earnings
Readouts

Sign In Subscribe

pharmadog

fetch the data · sniff the signal

Discover

Calendar
Drugs
Companies
News

Hubs

Topics
Jobs
Patent cliff
Publications

Tools

Compare
Search
Bookmarks

Trust

About
Sources
Contact

Legal

Privacy
Terms
Pricing

© 2026 pharmadog.xyz

made by humans and a good dog

home
jobs
news
cal
search

Jelmyto · pharmadog

pharmadog
drugs
Jelmyto

drug

patient view →

Jelmyto

Marketedupdated 2mo ago

by $URGN UroGen Pharma Ltd.

Approved

community read0 votes

Small molecule drug with a maximum clinical stage of Approval (across all indications), with 5 approved and 32 investigational indications.

all catalysts(1)

phase 3 initiation · 1

phase 3 initiation

All India Institute of Medical Sciences Bathinda — mitomycin (Phase III Trial Initiation)

News(0)

no news has mentioned this drug yet

brand

Jelmyto

generic

mitomycin

indication

Transitional Cell Carcinoma (Urothelial Cell Carcinoma)

phase

marketed

Patent cliff

source: FDA Orange Book

first barrier falls

Jul 19, 2026

12 days

Earliest of all listed patents + FDA exclusivities. Generic / biosimilar entry typically only becomes possible AFTER both patent and exclusivity barriers expire.

patents (12)

Jan 20, 2031method-of-use (U-4256)US 100398324.5y
Jan 20, 2031method-of-use (U-4172)US 122687454.5y
Jan 20, 2031method-of-use (U-4256)US 124405684.5y
Jan 20, 2031formulationUS 90400744.5y
Jan 20, 2031formulationUS 90400744.5y
Jan 20, 2031formulationUS 99500694.5y
Jan 20, 2031formulationUS 99500694.5y
May 21, 2029method-of-use (U-2095)US 96494282.9y
Feb 1, 2029formulationUS 78062652.6y
Jan 2, 2028compositionUS 95392411.5y
Jul 19, 2026formulationUS 818651112d
Jul 19, 2026formulationUS 920507512d

FDA exclusivities (2)

Jun 12, 2028NPNP1.9y
Apr 15, 2027ODE-289Orphan Drug (7y)282d

comments(0)

5-min edit window · permanent after that

sign in to leave a comment · permanent archive after 5 minutes

no comments yet — first sniff?

Data sources

ClinicalTrials.gov

last refreshed 1h ago

Found something off?

🐶 something off?

Report a data issue

Tell Bork what looks wrong — wrong sponsor, stale phase, mislinked ticker, anything. We’ll triage and fix.

🐶 often sniffed alongside

top 7

companyAll India Institute of Medical Sciences1 co-mentions · 1 sources
companyAll India Institute of Medical Sciences Bathinda1 co-mentions · 1 sources
tagOphthalmology1 co-mentions · 1 sources
drugUGN-1031 co-mentions · 1 sources
drugUGN-1041 co-mentions · 1 sources
drugmitomycin1 co-mentions · 1 sources
drugmitomycin SR1 co-mentions · 1 sources

Trials studying Jelmyto

phase3Efficacy and Safety of Pembrolizumab (MK-3475) in Combination With Chemoradiotherapy (CRT) Versus CRT Alone in Muscle-invasive Bladder Cancer (MIBC) (MK-3475-992/KEYNOTE-992)active not recruitingn=520
phase3A Study of TAR-200 Versus Intravesical Chemotherapy in Participants With Recurrent High-Risk Non-Muscle-Invasive Bladder Cancer (HR-NMIBC) After Bacillus Calmette-Guérin (BCG)active not recruitingn=272
phase3A Study to Evaluate TAR-210 Versus Intravesical Chemotherapy Treatment in Participants With High Risk Non-Muscle-Invasive Bladder Cancerrecruitingn=220
phase2A Study of Erdafitinib Versus Investigator Choice of Intravesical Chemotherapy in Participants Who Received Bacillus Calmette-Guérin (BCG) and Recurred With High Risk Non-Muscle-Invasive Bladder Cancer (NMIBC)completedn=107
phase3A Study of Intravesical SHR-1501 Combination With BCG Versus Investigator-selected Chemotherapy in Subjects With BCG-unresponsive NMIBCnot yet recruitingn=236
N/AAdaptive Radiation in Anal Cancerrecruitingn=20
phase4Chemoablation Or Bladder Resection With Adjuvant Chemotherapy in Recurrent Non-Muscle Invasive Bladder Cancerrecruitingn=272
phase2Study of SIB-IMRT in Combination With 5-FU and Mitomycin-C Among Patients With Locally Advanced Anal Canal Cancer: Efficacy, Safety and Quality of Lifeactive not recruitingn=71

more trials →